Insider Selling: Centessa Pharmaceuticals plc (NASDAQ:CNTA) Insider Sells $180,591.96 in Stock

Centessa Pharmaceuticals plc (NASDAQ:CNTA) insider Gregory M. Weinhoff sold 11,742 shares of the company’s stock in a transaction on Friday, October 25th. The shares were sold at an average price of $15.38, for a total transaction of $180,591.96. Following the completion of the sale, the insider now directly owns 183,266 shares in the company, valued at $2,818,631.08. This trade represents a 0.00 % decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which is accessible through the SEC website.

Centessa Pharmaceuticals Stock Performance

Shares of CNTA stock opened at $15.50 on Monday. The company has a current ratio of 13.29, a quick ratio of 13.29 and a debt-to-equity ratio of 0.27. Centessa Pharmaceuticals plc has a 12-month low of $5.58 and a 12-month high of $17.59. The business’s 50 day moving average is $15.04 and its two-hundred day moving average is $11.52. The company has a market capitalization of $1.56 billion, a P/E ratio of -10.92 and a beta of 1.46.

Centessa Pharmaceuticals (NASDAQ:CNTA) last announced its earnings results on Tuesday, August 13th. The company reported ($0.40) earnings per share (EPS) for the quarter, missing analysts’ consensus estimates of ($0.38) by ($0.02). Analysts expect that Centessa Pharmaceuticals plc will post -1.68 EPS for the current fiscal year.

Institutional Trading of Centessa Pharmaceuticals

Several institutional investors have recently modified their holdings of CNTA. Mirae Asset Global Investments Co. Ltd. raised its position in shares of Centessa Pharmaceuticals by 47.7% during the 3rd quarter. Mirae Asset Global Investments Co. Ltd. now owns 2,556 shares of the company’s stock worth $40,000 after purchasing an additional 826 shares during the last quarter. GAMMA Investing LLC increased its stake in Centessa Pharmaceuticals by 103.1% during the 3rd quarter. GAMMA Investing LLC now owns 2,972 shares of the company’s stock worth $48,000 after buying an additional 1,509 shares in the last quarter. Quarry LP raised its holdings in shares of Centessa Pharmaceuticals by 47.8% during the second quarter. Quarry LP now owns 9,608 shares of the company’s stock valued at $87,000 after acquiring an additional 3,108 shares during the last quarter. Sandia Investment Management LP purchased a new position in shares of Centessa Pharmaceuticals in the second quarter valued at approximately $90,000. Finally, Fred Alger Management LLC acquired a new stake in shares of Centessa Pharmaceuticals in the second quarter worth approximately $99,000. Institutional investors and hedge funds own 82.01% of the company’s stock.

Wall Street Analysts Forecast Growth

Several research firms have commented on CNTA. B. Riley started coverage on shares of Centessa Pharmaceuticals in a report on Thursday, September 19th. They issued a “buy” rating and a $33.00 price target on the stock. Jefferies Financial Group upped their target price on Centessa Pharmaceuticals from $13.00 to $19.00 and gave the stock a “buy” rating in a research note on Wednesday, September 11th. BMO Capital Markets lifted their price target on Centessa Pharmaceuticals from $20.00 to $35.00 and gave the company an “outperform” rating in a research report on Monday, September 16th. Oppenheimer restated an “outperform” rating and issued a $14.00 price objective on shares of Centessa Pharmaceuticals in a research report on Wednesday, August 14th. Finally, Guggenheim lifted their target price on shares of Centessa Pharmaceuticals from $20.00 to $24.00 and gave the company a “buy” rating in a report on Wednesday, September 11th. Six equities research analysts have rated the stock with a buy rating, According to data from MarketBeat.com, Centessa Pharmaceuticals has an average rating of “Buy” and an average price target of $25.17.

Centessa Pharmaceuticals Company Profile

Centessa Pharmaceuticals plc, a clinical-stage pharmaceutical company, discovers, develops, and delivers medicines for patients. Its products pipeline includes SerpinPC, an activated protein C inhibitor for the treatment of hemophilia A and B; and ORX750, an orally administered OX2R agonist for the treatment of narcolepsy and other sleep disorders.